Home/Pipeline/pre-miRNA targeting program

pre-miRNA targeting program

Undisclosed (within inflammation, autoimmune, cancer, or infection)

Pre-clinicalActive

Key Facts

Indication
Undisclosed (within inflammation, autoimmune, cancer, or infection)
Phase
Pre-clinical
Status
Active
Company

About Saverna Therapeutics

Saverna Therapeutics is a private, preclinical-stage biotech leveraging a unique AI- and NMR-driven platform to discover small molecule drugs targeting the largely unexplored non-coding RNA space, particularly microRNAs. Founded by a team of ex-Novartis scientists, the company aims to partner with larger pharmaceutical firms for discovery and early-stage development. To date, it has been financed through self-funding and public grants from Swiss and European innovation programs.

View full company profile